CHA Vaccine Research Institute (KOSDAQ:261780)
South Korea · Delayed Price · Currency is KRW 2,870.00
+100.00 (3.61%)
At close: Sep 17, 2025
KOSDAQ:261780 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Operating Revenue | 158.62 | 370.66 | 294.12 | 179.48 | 500 | 77.8 | Upgrade |
Other Revenue | -0 | -0 | -0 | -0 | - | - | Upgrade |
| 158.62 | 370.66 | 294.12 | 179.48 | 500 | 77.8 | Upgrade | |
Revenue Growth (YoY) | -57.21% | 26.02% | 63.87% | -64.10% | 542.70% | -38.31% | Upgrade |
Cost of Revenue | 14.7 | 23.93 | 34.5 | 19 | - | 13.01 | Upgrade |
Gross Profit | 143.92 | 346.73 | 259.62 | 160.49 | 500 | 64.79 | Upgrade |
Selling, General & Admin | 1,820 | 1,874 | 2,197 | 2,357 | 3,199 | 1,038 | Upgrade |
Research & Development | 7,453 | 5,678 | 3,949 | 3,855 | 3,140 | 3,124 | Upgrade |
Operating Expenses | 9,691 | 8,043 | 6,679 | 6,630 | 6,585 | 4,299 | Upgrade |
Operating Income | -9,547 | -7,696 | -6,419 | -6,469 | -6,085 | -4,234 | Upgrade |
Interest Expense | -1,855 | -1,288 | -2,631 | -2,567 | -2,122 | -837.2 | Upgrade |
Interest & Investment Income | 1,203 | 1,384 | 2,282 | 1,017 | 179.88 | 77.17 | Upgrade |
Currency Exchange Gain (Loss) | -0.48 | 10.02 | 2.67 | 0.02 | 0.17 | 0.04 | Upgrade |
Other Non Operating Income (Expenses) | -2,700 | -2,891 | 4,703 | 1,198 | -10,520 | -1,278 | Upgrade |
EBT Excluding Unusual Items | -12,899 | -10,481 | -2,063 | -6,821 | -18,546 | -6,272 | Upgrade |
Gain (Loss) on Sale of Investments | 254.25 | 66.77 | -40.4 | 105.84 | 125.77 | 31.7 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.32 | Upgrade |
Pretax Income | -12,644 | -10,414 | -2,103 | -6,715 | -18,420 | -6,240 | Upgrade |
Income Tax Expense | -275.5 | -275.5 | -353.77 | - | - | - | Upgrade |
Net Income | -12,369 | -10,138 | -1,749 | -6,715 | -18,420 | -6,240 | Upgrade |
Net Income to Common | -12,369 | -10,138 | -1,749 | -6,715 | -18,420 | -6,240 | Upgrade |
Shares Outstanding (Basic) | 27 | 27 | 27 | 26 | 23 | 18 | Upgrade |
Shares Outstanding (Diluted) | 27 | 27 | 27 | 26 | 23 | 18 | Upgrade |
Shares Change (YoY) | 0.24% | 1.10% | 0.26% | 13.39% | 30.03% | - | Upgrade |
EPS (Basic) | -461.31 | -378.30 | -66.00 | -254.00 | -790.00 | -348.00 | Upgrade |
EPS (Diluted) | -461.31 | -378.30 | -66.00 | -254.00 | -790.00 | -348.00 | Upgrade |
Free Cash Flow | -10,904 | -8,275 | -5,572 | -5,636 | -5,419 | -4,007 | Upgrade |
Free Cash Flow Per Share | -406.69 | -308.76 | -210.20 | -213.18 | -232.41 | -223.48 | Upgrade |
Gross Margin | 90.73% | 93.55% | 88.27% | 89.42% | 100.00% | 83.28% | Upgrade |
Operating Margin | -6018.68% | -2076.42% | -2182.53% | -3604.36% | -1216.93% | -5442.95% | Upgrade |
Profit Margin | -7797.99% | -2735.23% | -594.82% | -3741.36% | -3684.01% | -8021.36% | Upgrade |
Free Cash Flow Margin | -6874.65% | -2232.46% | -1894.38% | -3140.08% | -1083.83% | -5151.23% | Upgrade |
EBITDA | -9,129 | -7,205 | -5,886 | -6,052 | -5,839 | -4,094 | Upgrade |
D&A For EBITDA | 417.15 | 491.22 | 533.31 | 417.36 | 245.49 | 140.16 | Upgrade |
EBIT | -9,547 | -7,696 | -6,419 | -6,469 | -6,085 | -4,234 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.